aTYR PHARMA INC (ATYR) stock
ATYRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$4.99−0.25 (-4.77%)
Close on Nov 17, 2026Market cap $489.46MP/E –Yield –
aTYR PHARMA operating margin
Operating margin is operating income as a percentage of revenue.
aTYR PHARMA's operating margin for the twelve months ending Dec 31, 2025 was -40856.3%. For fiscal 2025 it was -40856.3%, against -28899.6% the year before. The highest annual figure on record is -152.2% in fiscal 2020.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -40856.3% | −11956.7 |
| FY2024 | Dec 31, 2024 | -28899.6% | −13341.8 |
| FY2023 | Dec 31, 2023 | -15557.8% | −15111.0 |
| FY2022 | Dec 31, 2022 | -446.8% | −294.6 |
| FY2020 | Dec 31, 2020 | -152.2% | +5292.8 |
| FY2019 | Dec 31, 2019 | -5445.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -14076.3% | −13835.7 |
| Q1 FY2024 | Mar 31, 2024 | -7079.1% | −2679.1 |
| Q3 FY2023 | Sep 30, 2023 | -3573.7% | −230.8 |
| Q4 FY2022 | Dec 31, 2022 | -76.5% | −99.6 |
| Q4 FY2020 | Dec 31, 2020 | -240.6% | +3899.7 |
| Q3 FY2020 | Sep 30, 2020 | -4400.0% | −1412.0 |
| Q2 FY2020 | Jun 30, 2020 | -3342.9% | +2658.2 |
| Q1 FY2020 | Mar 31, 2020 | 23.1% | – |
| Q4 FY2019 | Dec 31, 2019 | -4140.3% | – |
| Q3 FY2019 | Sep 30, 2019 | -2988.0% | – |
| Q2 FY2019 | Jun 30, 2019 | -6001.1% | – |
See a number that looks wrong?